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Available online 16 May 2011Abstract Background: G-CSF based stemcellmobilization and stabilization of cardiac SDF-1 byDPP-IV-inhibition (dual stem cell
therapy) improve heart function and survival after myocardial infarction. However, it is barely understood whether this new
approach acts specifically through the SDF-1/CXCR4 axis, stimulation of resident cardiac stem cells and improved myocardial
perfusion. Therefore, we aimed to clarify the role of the SDF1/CXCR4 axis with respect to the benefits of a dual stem cell based
therapy.
Methodology/principal findings: After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically
blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. G-CSF+DipA treated and non-
treated animals served as controls. Because AMD3100 is known to mobilize bone marrow derived stem cells (BMCs) in high
concentrations, the optimal dosage (1.25 mg per kg body weight) sufficient to block CXCR4 without stimulating mobilization was
established. AMD3100 treatment of G-CSF and Diprotin A stimulated mice significantly decreased myocardial homing of
circulating stem cells (FACS analysis) and inverted the beneficial effects of (i) cardiac remodeling (histological analyses), (ii)
heart function (Millar tip catheterization) and (iii) survival (Kaplan–Meier curves). G-CSF treatment in combination with DPP-IV
inhibition enhanced neovascularization at the infarct border zone which was related to an improved myocardial blood flow as
measured by SPECT. Moreover, dual stem cell treatment effectively stimulated the pool of resident cardiac stem cells (FACS)
which was reversed by AMD3100 treatment.
Conclusions/significance: Our data give final proof that homing through the SDF-1/CXCR-4 axis is essential for the success of
dual stem cell therapy.
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245Dual stem cell therapyIntroductionIn industrial nations, ischemic disorders in general are the
main cause of death in human beings (Dickstein et al., 2008).
After myocardial infarction, damages of cardiac tissue are
irreversible and lead to progressive ischemic cardiomyopa-
thy. However, stem cell mobilization and migration into the
heart could be a new therapeutic approach to improve
myocardial function and survival after ischemic injury since
they stimulate neovascularization and prevent apoptosis of
cardiomyocytes by paracrine means (Balsam et al., 2004;
Fazel et al., 2006; Murry et al., 2004; Zaruba et al., 2008).
While experiments using granulocyte-colony stimulating fac-
tor (G-CSF) based stem cell mobilization in mice showed great
promise (Deindl et al., 2006; Orlic et al., 2001), only few
human trials reported an improvement of cardiac function
(Ince et al., 2005a; Ince et al., 2005b), whereas most of them
could not demonstrate beneficial effects (Engelmann et al.,
2006; Engelmann et al., 2010; Zohlnhofer et al., 2008).
Recently, we advanced the approach of therapeutic stem
cell mobilization by contemporaneous enhancement of
cardiac homing capacity (Zaruba et al., 2009). Although
homing of circulating stem cells is mediated by several
parameters like stem cell factor (SCF) or hepatocyte growth
factor (HGF), the interaction of CXCR4 and myocardial
stromal cell-derived factor (SDF-1) appeared to be the
most relevant axis (Abbott et al., 2004; Aiuti et al., 1997;
Askari et al., 2003; Ceradini et al., 2004; Franz et al., 2003;
Saxena et al., 2008; Segers et al., 2007). SDF-1 binds to CXCR-
4 in its active form (1–68) (Crump et al., 1997) and is cleaved
N-terminally at its position-2 proline by CD26/dipeptidylpep-
tidase IV (DPP-IV), which is a membrane-bound extracellular
peptidase (Christopherson et al., 2004) that is ubiquitously
expressed (Huhn et al., 2000; Kahne et al., 1999; Ruiz et al.,
1998; Vanham et al., 1993). Combining genetic or pharmaco-
logical inhibition of CD26/DPP-IV with G-CSF based stem cell
mobilization, we could demonstrate stabilization of myocar-
dial SDF-1, enhanced cardiac recruitment of bone marrow-
derived stem cells, improved myocardial function and in-
creased survival in the mouse model (Zaruba et al., 2009).
Thereupon, we transferred this new approach from bench to
bedside and initiated the first study (SITAGRAMI-Trial)
analyzing dual stem cell therapy in patients suffering from
acute myocardial infarction (Theiss et al., 2010).
However, we aimed to collect further evidence that the
beneficial effects of this innovative dual therapeutic concept
are specifically due to cardiac homing of bone-marrow derived
stem cells via the SDF-1/CXCR4 axis since G-CSF and/or DPP-IV
inhibition may exert direct effects on ischemic myocardium as
well. Therefore, we antagonized specifically the CXCR4
receptor using AMD3100 after ligation of the left anterior
descending artery (LAD) in mice and analyzed stem cell
homing, infarct size, cardiac function and survival. Addition-
ally, we analyzed the effect of a dual stem cell therapy on
capillary formation and myocardial perfusion using SPECT
technology. Finally, we intended to elucidate the role of
resident cardiac stem cells after DPP-IV inhibition and G-CSF
application. We hypothesized that the increased homing of
bone-marrow derived stem cells also leads to a paracrine
stimulation of resident cardiac stem cells, which also may
contribute to the improvement of heart function and survival.Results
Dose–response titration of AMD3100 with respect
to stem cell mobilization
First,weaimed toestablish theoptimal dosageof AMD3100 that
is sufficient to block CXCR4 without stimulating the mobiliza-
tion of stem cells to a relevant extent (Broxmeyer et al., 2005).
AMD3100 concentrations of 0.5, 1.25 and 5.0 mg/kg/d were
administered and analyzed for the amount of CD34+/CD45+ and
CD34+/CD45+/CXCR4+ stem cells in the peripheral blood at day
2 after MI (Fig. 1).
UsingAMD3100 concentrations of 0.5 and 1.25 mg/kg/d,we
detected no relevant mobilization of CD34+/CD45+/CXCR-4+
progenitor cells and only slight mobilization of CD34+/CD45+
cells (using 1.25 mg/kg/d). In contrast, application of
5.0 mg/kg AMD3100 leads to a 10-fold increase of circulating
CD34+/CD45+ and CD34+/CD45+/CXCR-4+ stem cells. On this
basis, we used AMD3100 at the concentration of 1.25 mg/kg/d
for further experiments.
AMD3100 antagonizes the benefit of DPP-IV inhibition
on cardiac SC homing
Second, we analyzed the impact of AMD3100 administration on
the myocardial homing of bone marrow derived stem cells. As
shown in Fig. 2, application of G-CSF andDiprotin A significantly
increased the numbers of bone-marrow derived CD34+/CD45+,
CD34+/CD45+/CXCR4+ as well as lin−/Sca-1+/c-kit+ stem cell
populations in the heart not only at day 2 (as shown previously)
(Zaruba et al., 2009) but also even at day 6 after MI (Fig. 2). This
effect was significantly inverted by AMD3100 based CXCR4
antagonization. The relative numbers of CD34+/CD45+ (1.32±
0.31% vs. 4.94±1.19%, pb0.05), CD34+/CD45+/CXCR-4+ (0.95±
0.31% vs. 4.16±1.06%, pb0.05) and lin−/Sca-1+/c-kit+ (0.17±
0.03 vs. 0.66±0.21, pb0.05) stem cells were significantly
decreased in the [AMI+G-CSF+DipA+AMD] group compared to
[AMI+G-CSF+DipA] animals suggesting specific inhibition of the
SDF1–CXCR4-axis. Sole AMD3100 administration did not lead to
significant effects in comparison to the saline group.
CXCR4 antagonism increased the size of infarction
and led to pronounced wall thinning
Next, we investigated the effect of a CXCR4 antagonism with
respect to LV remodeling after MI. In [AMI+G-CSF+DipA]
animals, the size of infarctionwas significantly reduced 30 days
after MI in comparison to the control group (Fig. 3). As shown in
Fig. 3A, blocking of CXCR4 by AMD3100 significantly increased
the size of infarction in the [AMI+G-CSF+DipA+AMD] group
compared to [AMI+G-CSF+DipA] (32.3±4.1% vs. 23.4±1.5%,
pb0.05). In parallel, histological analyses revealed a signifi-
cant LVwall thinning in [AMI+G-CSF+DipA+AMD] treatedmice
as compared to the [AMI+G-CSF+DipA] group at day 30 after MI
(0.43±0.01 mmvs. 0.22±0.03 mm, pb0.05). Interestingly, the
[AMI+G-CSF+DipA+AMD] group revealed similar values with
respect to the infarct size and the LV wall thickness as G-CSF
mono treated animals, suggesting that the additional benefits
on cardiac remodeling are mainly due to stabilization of the
SDF-1/CXCR4 axis by DPP-IV inhibition.
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Figure 1 Dose–response titration of AMD3100 concerning stem cell mobilization. (A) Diagrams show the amount of bone marrow
derived CD34+/CD45+ (upper row) and CD34+/CD45+/CXCR-4+ (lower row) stem cells in different concentrations of AMD3100 (0.5, 1.25
and 5.0 mg/kg) and in controls in the peripheral blood 2 days after myocardial infarction. Data represent mean±SEM (n=6); [*]=
pb0.05; [ns]=not significant. (B) Representative FACS plots showing the mean numbers of CD34+/CD45+ cells in the peripheral blood
of mice treated with saline or AMD3100 in different concentrations (0.5, 1.25 and 5.0 mg/kg).
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Figure 2 CXCR4 antagonization reverses cardiac SC homing in G-CSF+DipA treated mice. Histograms representing the percentage of
myocardial CD34+/CD45+ (A), CD34+/CD45+/CXCR-4+ (B) as well as lin−/c-kit+/Sca-1+ (C) bone marrow derived stem cells 6 days after
myocardial infarction. Data represent mean±SEM (n=8); [*]=pb0.05; [ns]=not significant.
247Dual stem cell therapyBlockage of SDF-1/CXCR-4 inverts the improvement
of cardiac function
Having shown that CXCR4 antagonism impaired LV remodel-
ing, we next evaluated the impact of AMD3100 treatment on
cardiac function. Using conductance catheters, pressure
volume relations were measured from [AMI+saline], [AMI+G-CSF], [AMI+G-CSF+DipA] and [AMI+G-CSF+DipA+AMD]
groups (each n=10) at day 30 after MI (Figs. 4A and B).
Administration of AMD3100 inverted the improvement of
ejection fraction in the [AMI+G-CSF+DipA] group (23.3±
2.6% vs. 35.0±3.3%, pb0.05). As another control group, sole
administration of AMD3100 did not influence cardiac function
significantly.
AB
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Figure 3 Effect of AMD3100 on the size of myocardial infarction and LV wall thickness. (A) and (B) Bar graphs representing the size of
myocardial infarction as well as the thickness of the LV wall 30 days after myocardial infarction. Data represent mean±SEM (n=8); [*]=
pb0.05; [ns]=not significant. (C) Representative histological Masson's trichrome stainings of transverse heart sections in infarcted
hearts 30 days after myocardial infarction.
248 H.D. Theiss et al.In analogy, contractility and effective arterial elastance
were declined in the [AMI+G-CSF+DipA+AMD] group. Dia-
stolic heart function reflected by the isovolumetric relaxa-
tion parameter Tau weiss was also impaired (Suppl. 2). Thus,
[AMI+G-CSF+DipA+AMD] mice showed a significantly de-
creased systolic and diastolic function in comparison to the
[AMI+G-CSF+DipA] group.
AMD3100 application reverts advantage of survival
Cumulative survival of saline, G-CSF, G-CSF+DipA and G-CSF+
DipA+AMD3100 treated mice (each with n=23) was recorded
for 30 days after ligation of LAD (Fig. 4C). Mortality was very
high within the first 6 days after MI. The high early post-MImortality is mainly due to ruptures of the left ventricle wall or
cardiac arrhythmias. The [AMI+G-CSF+DipA] group showed
highly increased survival rates (69.6%) in comparison to the
saline treated group (34.8%). Notably, this effect was
completely reversed by application of the CXCR-4 antagonist
AMD3100. Only 39.1% of [AMI+G-CSF+DipA+AMD] mice were
alive 30 days after MI, which is comparable to the G-CSF
monotherapy.
Blockage of SDF-1/CXCR-4 axis reduces cardiac
neovascularization
Since CD34+/CD45+ cells are known carriers of growth
factors, we next evaluated the amount of neovascularization
CA
B
Figure 4 Analysis of cardiac function and survival after AMD3100 administration. (A) Bar graph representing the ejection fraction (EF) of
[AMI+saline], [AMI+G-CSF], [AMI+G-CSF+DipA], [AMI+G-CSF+DipA+AMD] and [AMI+AMD] treated mice after ligation of LAD at day 30.
Data represent mean±SEM; n=10; [*]=pb0.05; [ns]=not significant. (B) Representative pressure volume loops of the aforementioned
groups 30 days after myocardial infarction. (C) Kaplan–Meier curves showing survival rates of [AMI+saline], [AMI+G-CSF], [AMI+G-CSF+
DipA] and [AMI+G-CSF+DipA+AMD] mice 30 days after acute myocardial infarction. All mice (n=23 each group) revealed histologically
confirmed myocardial infarctions.
249Dual stem cell therapyand perfusion in the infarcted heart. G-CSF treatment and
application of Diprotin A lead to significantly increased
numbers of CD31 positive capillaries in the border zone ascompared to non-treated animals or [AMI+G-CSF] mice
(Fig. 5). The effect on neovascularization was reversed
when CXCR4 was antagonized by AMD3100.
AB
Figure 5 G-CSF and Diprotin A treatment enhance neovascularization. (A) Histogram shows that the numbers of CD31+ capillaries in
the infarct border zone is increased in [AMI+G-CSF+DipA] animals compared to [AMI], [ AMI+G-CSF] and [AMI+G-CSF+DipA+AMD]
mice. [*]=pb0.05 (B) Representative immunohistochemical staining of CD31-positive capillaries (brown) in infarcted hearts 6 days
after myocardial infarction.
250 H.D. Theiss et al.Additionally, myocardial perfusion was repetitively and
longitudinally analyzed by a clinical SPECT system equipped
with pinhole collimators (Wollenweber et al., 2010). As shown
in Fig. 6, myocardial perfusion exclusively decreased in the
[AMI] group 30 days after MI (Fig. 6). In contrast, myocardial
perfusion was markedly increased in [AMI+G-CSF+DipA] mice
compared to both [AMI+G-CSF] and [AMI+G-CSF+DipA+AMD]
mice. The decrease of myocardial perfusion in mice treated
with the CXCR4 inhibitor AMD3100 suggests that the effects of
dual stem cell therapy on myocardial perfusion are also
dependent on an intact SDF1/CXCR4 axis.
Dual stemcell therapy stimulates CD34−/CD45−/c-kit+
and CD34−/CD45−/Sca1+ cells
G-CSF based stem cell mobilization combined with DPP-IV
inhibition leads to a highly significant increase of so called
resident cardiac stem cells (RCSC) defined as a population of
CD34−/CD45−/c-kit+ cells or CD34−/CD45−/Sca1+ cells (Fig. 7).In comparison, after administration of AMD3100 only moderate
enhancement of these cells was detected in the [AMI+G-CSF+
DipA+AMD] group, which was in the same range as in [AMI+
G-CSF] animals. Sole administration of AMD showed no relevant
effect on RCSC (Fig. 8).
Discussion
Recently, we established the new therapeutic concept of a
dual stem cell therapy after acute myocardial infarction
which combines G-CSF induced stem cell mobilization and
pharmacological SDF-1 stabilization by DPP-IV inhibition
(Zaruba et al., 2009). However, the precise mechanisms of
SDF-1/CXCR4 mediated cardiac repair are still barely
understood. Therefore, we aimed to elucidate three impor-
tant questions which remained open: 1. Were the effects of
dual stem cell therapy on cardiac function and survival
specifically exerted via the SDF1/CXCR4 axis? 2. Which role
do neovascularization and myocardial perfusion play in
AB
Figure 7 Dual stem cell therapy stimulates resident cardiac stem cells. Resident cardiac stem cells are defined as a populations
of CD34−/CD45−/c-kit+ and CD34−/CD45−/Sca1 +cells. The diagram shows that G-CSF+DipA treatment leads to a significant
increase of resident cardiac stem cells in comparison to the [AMI+saline] group (n=8). This effect can be inverted by AMD
administration.
Figure 6 Dual stem cell therapy improves myocardial perfusion. Myocardial perfusion is enhanced in [AMI+G-CSF+DipA] mice
compared to the other groups 30 days after myocardial infarction (assessed by gated single photon emission computed tomography
(SPECT)). [*]=pb0.05.
251Dual stem cell therapy
Figure 8 Schematic overview of SDF-1/CXCR4 mediated cardiac repair. Dual stem cell therapy works by two basic mechanisms.
Application of G-CSF leads to stem cell mobilization from bone marrow into peripheral blood. DPP-IV inhibition (using Diprotin A)
stabilizes myocardial SDF-1 thereby improving the cardiac homing of mobilized stem cells. After homing, mobilized stem cells
stimulate resident cardiac stem cells, enhance myocardial perfusion and reduce cardiac remodeling. All these effects lead in addition
to improved cardiac function and survival after myocardial infarction. This can be inverted by application of the CXCR4-antagonist
AMD3100, which shows the dependence of a dual stem cell therapy on an intact SDF-1/CXCR4-axis.
252 H.D. Theiss et al.CXCR4mediated repair? 3. Does dual stem cell therapy affect
the pool of resident cardiac stem cells?Dual stem cell therapy works specifically by the
SDF1–CXCR4-axis
In the current study, we applied the CXCR4 antagonist
AMD3100 to specifically block CXCR4 mediated interactions.
In other studies, AMD3100 was used for mobilizing stem cells
from the bonemarrow into peripheral blood (Broxmeyer et al.,
2005). However, in these experiments AMD3100 was used at
high concentrations of 5 mg/kg. In order to minimize the
effects of AMD3100 on stem cell mobilization, we performed
dose–response experiments to establish the highest possible
dosage of AMD3100 that has negligible effects on stem cell
mobilization. In our hands, an AMD3100 applied at a dosage of
1.25 mg/kg/d revealed low mobilizing activity and seemed
sufficient for effective CXCR-4 antagonization. On this basis,
we used AMD3100 at a concentration of 1.25 mg/kg to
specifically block CXCR4 in our experiments.
Application of AMD3100 leads to reduced myocardial
homing of circulating stem cells, impaired post-MI remodeling
and deterioration of cardiac function as well as survival. These
data suggest that the combined application of G-CSF and
Diprotin A mainly works through an intact SDF1/CXCR4 axis
although other factors like HGF or SCF also contribute to the
homing process. Our results further underline the importance
of combining G-CSF and DPP-IV inhibition. Apparently, theextent of stem cell homing is decisive for the success of our
therapeutic approach although other direct cardiac effects of
G-CSF (Harada et al., 2005) and Diprotin A also may exist.Myocardial perfusion is enhanced by dual stem cell
therapy
Another crucial question is to which extent different mecha-
nisms contribute to the success of dual stem cell therapy. One
essential factor is myocardial perfusion since rescued cardio-
myocytes and resident cardiac stem cells definitively need
enough blood supply to regenerate the infarcted myocardium.
First, we showed that the increase of CD31 positive capillaries
induced by dual stem cell therapy in the border zone could be
reversed by CXCR4 antagonization suggesting that the effects
on neovascularization are specifically mediated through an
intact SDF-1/CXCR4 axis. Secondly, we analyzed myocardial
perfusion by SPECT analysis, which is very compelling because
measurements can be performed at several time points in the
same animal. Our group has previously shown that SPECT
analysis is applicable for perfusion studies after myocardial
infarction (Wollenweber et al., 2010). Using this method, we
now examined the time course of cardiac blood flow over
30 days after myocardial infarction under G-CSF therapy and
DPP-IV-inhibition. Notably, dual stem cell therapy enhanced
myocardial perfusion after 30 days in comparison to non-treated
animals ormice receivingG-CSF-monotherapy.These results are
very important since the combination of improved blood flow in
253Dual stem cell therapythe (peri) infarct zoneand regenerationofmyocardiumseems to
be crucial for true repair of infarcted hearts.
Dual stem cell therapy stimulates “resident cardiac
stem cells”
Finally, we analyzed the impact of this new therapeutic
approach on so called resident cardiac stem cells (RCSC).
Using the combination of G-CSF and Diprotin A, the numbers
of RCSC characterized as CD34−/CD45−/c-kit+ and
CD34−/CD45−/Sca1+ cells were significantly increased. Again
these results were inverted after AMD3100 application.
Apparently, our approach enhances the amount of RCSCs
specifically by the SDF-1α/CXCR-4 axis. On the one hand, our
strategy yields improved cardiac homing ofmobilized stemcells
which may stimulate RCSC by paracrine means. On the other
hand, Tang et al. recently showed that c-kit+ RCSC highly
express CXCR4 after hypoxic preconditioning (Tang et al.,
2009). Notably, they showed the importance of SDF-1/CXCR4
signaling for RCSC effects on ischemic myocardium which were
abolished after in vitro application of AMD3100. These results
perfectlymatchwith our findings that RCSC activation byG-CSF
and Diprotin A application is dependent on the SDF-1/CXCR-4
axis. These data are important since there is evidence that
resident cardiac stem cells play a crucial role for cardiac
renewing (Beltrami et al., 2003;Messina et al., 2004). Theymay
stimulate cardiomyocytes via paracrine mechanisms and
furthermore may have the potential to differentiate into
cardiomyocytes, endothelial or smooth muscle cells in the
ischemic heart. However, future studies comprising immuno-
histological evaluation and cell tracing studies have to analyze
these possible effects after dual stem cell therapy in detail.
In summary, our experiments suggest that the beneficial
effects of dual stem cell therapy on stem cell homing, cardiac
remodeling, heart function and survival are mainly mediated
through CXCR4 dependent mechanisms. Therefore, our data
strengthen the concept of dual stem cell therapy comprising
G-CSF based stem cell mobilization and pharmacological DPP-
IV inhibition as a new carrier of hope for treatment after acute
myocardial infarction (Theiss et al., 2010).
Materials and methods
Animal model
Animal care and all experimental procedures were performed
in strict accordance to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996). C57BL/6
micewere purchased fromCharles River (Sulzfeld, Germany).
Myocardial infarction (MI) was induced in 8–10 weeks old
male C57BL/6 mice by surgical occlusion of the LAD as
described previously (Deindl et al., 2006). All experiments
concerning survival and cardiac function were performed by
the same operator.
Administration of G-CSF, Diprotin A and AMD3100
Experimental design is shown in Supplement 1. Mice were
randomly divided into the following groups: Infarcted C57Bl/6mice (n=20) [AMI] receiving either saline (0.9% NaCl), G-CSF
(100 μg/kg/d i.p.) alone [AMI+G-CSF], G-CSF+Diprotin A
(70 mg/kg/twice perday) [AMI+G-CSF+DipA],G-CSF+Diprotin
A+AMD3100 (1.25 mg/kg/d p.i.) or only AMD3100 [AMI+AMD]
for up to 6 days. G-CSF and/or Diprotin A and/or AMD3100
treatment was initiated immediately after the surgical
procedure. For analysis of the [AMI], [AMI+G-CSF] and [AMI+
G-CSF+DipA] control groups we used data from the animal
stocks that have contributed to our previous publication
(Zaruba et al., 2009) but also added new animals.
Functional parameter
For evaluation of pressure–volume relationships in vivo, mice
were anesthetized with thiopental (100 mg/kg, i.p.), intu-
bated and ventilated (MiniVent, HUGO SACHS, Freiburg,
Germany). After catheterization via the right carotid artery
an impedance-micromanometer catheter (Millar Instruments,
Houston, Texas) was introduced into the left ventricle. Raw
conductance volumeswere corrected for parallel conductance
by the hypertonic saline dilution method as described
previously (Zaruba et al., 2008). Hemodynamicmeasurements
as well as data analyses were performed by a blinded person
using PVAN analysis software (HUGO SACHS, March, Germany).
Histology and immunohistochemistry
At day 30, hearts were excised (n=6 in each group). After
fixation in 4% phosphate buffered formalin the hearts were
cut transversally into 2 mm thick slices and embedded in
paraffin. 4 μm thick sections were cut and mounted on
positively charged glass slides. Standard histological pro-
cedures (haematoxylin/eosin and Masson trichrome) and
immunostaining were executed. Infarct size was determined
as area of infarction (AI) correlated to the area of the left
ventricle (including LV-septum) in four different slices from
the base to the apex of a heart. Total infarct size was
calculated by multiplication of the mean percentage value of
the circular infarct area with the ratio: vertical extension of
the infarct area/total ventricular extension. Measurement of
wall thickness was performed by taking the average length of
five segments along radii from the center of the left ventricle
through the thinnest points of the free LV wall. As analyzed
and reported previously, initial infarct sizes are comparable
between the different treatment groups as assessed 6 days
after myocardial infarction (Zaruba et al., 2009).
For immunostaining, antibodies against CD31 (goat anti-
mouse, Santa Cruz) were used. 10 random high-power fields
(HPF) from the border zone of each heart sample (n=6) were
analyzed concerning the numbers of CD31+ capillaries with
400× magnification as previously described (Zaruba et al.,
2009).
Perfusion measurement by single photon emission
computed tomography (SPECT)
Imaging was performed 6 and 30 days after LAD ligation as
previously described (Wollenweber et al., 2010). Each
animal was injected with approximately 370 MBq [99mTc]
sestamibi (Covidien, Neustadt/Donau, Germany) in the tail
vein. 45 min after injection, the mouse was positioned in the
254 H.D. Theiss et al.scanner. Wemeasured left ventricular perfusion using a triple-
headed single-photon emission computed tomography system
(Prism 3000XP, Philips Medical Systems, Hamburg, Germany).
Each detector head was equipped with a 0.5-mm diameter
custom-made tungsten knife-edge pinhole collimator (Nuclear
Fields, Vortum-Mullem, Holland). The radius of rotation was
set to 4 cm (magnification 4-fold), and data were acquired
over 60 projection angles (120° for each head), 90 s per
projection, giving a total acquisition time of 30 min. Zoom
factor was set as 2.0. Center of rotation error was corrected by
scanning a multiple point phantom and iteratively adjusting
the center-of-rotation offsets. We used the same source to
measure the spatial resolution of the system for [99mTc].
Images consisted of amatrix of 128×128×128with an isotropic
voxel size of 0.445 mm. All images were reconstructed using
six iterations. Attenuation and scatter correction were not
performed in any studies.
Dedicated software was used to generate transverse
slices. A volumetric sampling tool was applied to create
polar maps of the relative distribution of activity throughout
the left ventricle (Nekolla et al., 1998). Each polar map was
adjusted for its own maximal value. The size of the defect
was calculated with the use of a threshold of 65%, which was
derived from the histological infarct sizes. Δ Perfusion was
calculated as defect size in % [6 days] — defect size in %
[30 days].
Flow cytometry (FACS) of peripheral blood and non-
myocyte cardiac cells
8 to 10 weeks old C57BL/6mice (n=8)were treatedwith saline,
G-CSF, Diprotin A, AMD3100 or combined daily for 6 days. Cells
were separated from peripheral blood as described previously
(Deindl et al., 2006). The followingmonoclonal antibodieswere
used: CD45-PerCP, CD34-FITC, CXCR4-PE (all from BD Pharmin-
gen). Matching isotype antibodies (BD Pharmingen) served as
controls. Cells were analyzed by 3-color flow cytometry using a
Coulter® Epics® XL-MCLTM flow cytometer (Beckman Coulter).
Each analysis included 50,000 events.
Cardiac cells of infarcted hearts of C57BL/6 mice were
analyzed 6 days after MI (n=8). Therefore, a myocyte-depleted
cardiac cell population was prepared, incubating minced
myocardium in 0.1% collagenase IV (Gibco BrL) 45 min at
37 °C, lethal to most adult mouse cardiomyocytes (Zhou et al.,
2000). Cells were then filtered through a 70-μm mesh. To
exclude spurious effects of enzymatic digestion, BMcellswith or
without collagenase treatment were stained revealing no
significantly changed staining of labeled cell antigens (data
not shown). Cells were stained with CD45-PerCP, CD34-FITC,
c-kit-PE, CXCR4-PE, Sca1-PE, CD3-biotin, CD45R/B220-biotin,
CD11b-biotin, TER-119-biotin, Ly-6G-biotin Abs (all from BD
Pharmingen) and subjected to flow cytometry using EPICS
XLMCL flow cytometer and Expo32 ADC Xa software (Beckman
Coulter). Each analysis included 50,000 events.
Statistical analyses
Results were expressed as mean±SEM (standard error of
mean). Multiple group comparisons were performed by one-
way analyses of variance (ANOVA) followed by the Bonferroni
procedure for comparison of means. Comparisons betweentwo groups were performed using the unpaired Student's
t-test. Data were considered statistically significant at a
value of p≤0.05. Analysis of mortality was performed by the
Kaplan–Meier-method.Funding
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